Krystle A Lang Kuhs1, Michael Pawlita2, Sandra P Gibson3, Nicole C Schmitt4, Sumita Trivedi5, Athanassios Argiris6, Aimée R Kreimer1, Robert L Ferris7, Tim Waterboer8. 1. National Cancer Institute, NIH, 9609 Medical Center Drive, Bethesda, MD 20892, USA. 2. German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120 Heidelberg, Germany. 3. University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Pittsburgh, PA 15232, USA. 4. University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Pittsburgh, PA 15232, USA; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, 6420 Rockledge Drive, Suite 4920, Bethesda, MD, USA; Tumor Biology Section, National Institute of Deafness and Communication Disorders, National Institutes of Health, 10 Center Drive, Building 10, Room 5B39, Bethesda, MD, USA. 5. Department of Otolaryngology and Cancer Immunology Program, University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, PA 15232, USA. 6. University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; Hygeia Hospital, Erythrou Stavrou 5, Athens 15123, Greece. 7. University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Pittsburgh, PA 15232, USA. Electronic address: ferrrl@upmc.edu. 8. German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120 Heidelberg, Germany. Electronic address: t.waterboer@dkfz-heidelberg.de.
Abstract
BACKGROUND: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized. METHODS: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n=25). RESULTS: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n=6] and 100% [95% CI: 60-100%, n=4] compared to 0% (n=2) and 0% (n=13) for non-OPC cases. CONCLUSIONS: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.
BACKGROUND:Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized. METHODS: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n=25). RESULTS: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n=6] and 100% [95% CI: 60-100%, n=4] compared to 0% (n=2) and 0% (n=13) for non-OPC cases. CONCLUSIONS:HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.
Authors: Athanassios Argiris; Dwight E Heron; Ryan P Smith; Seungwon Kim; Michael K Gibson; Stephen Y Lai; Barton F Branstetter; Donna M Posluszny; Lin Wang; Raja R Seethala; Sanja Dacic; William Gooding; Jennifer R Grandis; Jonas T Johnson; Robert L Ferris Journal: J Clin Oncol Date: 2010-11-15 Impact factor: 44.544
Authors: Tim Waterboer; Peter Sehr; Kristina M Michael; Silvia Franceschi; John D Nieland; Thomas O Joos; Markus F Templin; Michael Pawlita Journal: Clin Chem Date: 2005-08-11 Impact factor: 8.327
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Rossana Verónica Mendoza López; José Eduardo Levi; José Eluf-Neto; Rosalina Jorge Koifman; Sergio Koifman; Maria Paula Curado; Pedro Michaluart-Junior; David Livingstone Alves Figueiredo; Fabiano Pinto Saggioro; Marcos Brasilino de Carvalho; Luiz Paulo Kowalski; Márcio Abrahão; Francisco de Góis-Filho; Eloiza Helena Tajara; Tim Waterboer; Paolo Boffetta; Paul Brennan; Victor Wünsch-Filho Journal: Cancer Causes Control Date: 2014-01-29 Impact factor: 2.506
Authors: Maura L Gillison; Laia Alemany; Peter J F Snijders; Anil Chaturvedi; Bettie M Steinberg; Steve Schwartz; Xavier Castellsagué Journal: Vaccine Date: 2012-11-20 Impact factor: 3.641
Authors: Gypsyamber D'Souza; Gwendolyn Clemens; Tanya Troy; Rachel G Castillo; Linda Struijk; Tim Waterboer; Noemi Bender; Phillip M Pierorazio; Simon R Best; Howard Strickler; Dorothy J Wiley; Robert I Haddad; Marshall Posner; Carole Fakhry Journal: Cancer Prev Res (Phila) Date: 2019-08-16
Authors: Karen S Anderson; Garrick Wallstrom; Hilde Langseth; Marshall Posner; Julia N Cheng; Rizwan Alam; Diego Chowell; Ingegerd E Furre; Jon Mork Journal: Oral Oncol Date: 2017-09-01 Impact factor: 5.337
Authors: Yuehan Zhang; Tim Waterboer; Robert I Haddad; Brett A Miles; Alicia Wentz; Neil D Gross; Carole Fakhry; Harry Quon; Jochen H Lorch; Christine G Gourin; Daniel Clayburgh; Krzysztof J Misiukiewicz; Jeremy D Richmon; Peter E Andersen; Marshall R Posner; Gypsyamber D'Souza Journal: Oral Oncol Date: 2017-02-15 Impact factor: 5.337
Authors: Kristina R Dahlstrom; Karen S Anderson; Matthew S Field; Diego Chowell; Jing Ning; Nan Li; Qingyi Wei; Guojun Li; Erich M Sturgis Journal: Cancer Date: 2017-09-12 Impact factor: 6.860
Authors: Daniel C Beachler; Tim Waterboer; Christine M Pierce Campbell; Donna J Ingles; Krystle A Lang Kuhs; Alan G Nyitray; Allan Hildesheim; Michael Pawlita; Aimée R Kreimer; Anna R Giuliano Journal: Papillomavirus Res Date: 2016-07-28
Authors: Pia Marie Albano; Christianne Salvador; Jose Orosa; Sheryl Racelis; Modesty Leaño; Angelika Michel; John Donnie Ramos; Dana Holzinger; Michael Pawlita Journal: J Pathol Transl Med Date: 2019-05-30